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A B S T R A C T
Transient outward potassium current (Ito) contributes to early repolarization of many mammalian cardiac action
potentials, including human, whilst the rapid delayed rectiﬁer K+ current (IKr) contributes to later repolariza-
tion. Fast Ito channels can be produced from the Shal family KCNDE gene product Kv4.3s, although accessory
subunits including KChIP2.x and DPP6 are also needed to produce a near physiological Ito. In this study, the
eﬀect of KChIP2.1 & KChIP2.2 (also known as KChIP2b and KChIP2c respectively), alone or in conjunction with
the accessory subunit DPP6, on both Kv4.3 and hERG were evaluated. A dual Ito and IKr activator, NS3623, has
been recently proposed to be beneﬁcial in heart failure and the action of NS3623 on the two channels was also
investigated. Whole-cell patch-clamp experiments were performed at 33 ± 1 °C on HEK293 cells expressing
Kv4.3 or hERG in the absence or presence of these accessory subunits. Kv4.3 current magnitude was augmented
by co-expression with either KChIP2.2 or KChIP2.1 and KChIP2/DPP6 with KChIP2.1 producing a greater eﬀect
than KChIP2.2. Adding DPP6 removed the diﬀerence in Kv4.3 augmentation between KChIP2.1 and KChIP2.2.
The inactivation rate and recovery from inactivation were also altered by KChIP2 isoform co-expression. In
contrast, hERG (Kv11.1) current was not altered by co-expression with KChIP2.1, KChIP2.2 or DPP6. NS3623
increased Kv4.3 amplitude to a similar extent with and without accessory subunit co-expression, however
KChIP2 isoforms modulated the compound’s eﬀect on inactivation time course. The agonist eﬀect of NS3623 on
hERG channels was not aﬀected by KChIP2.1, KChIP2.2 or DPP6 co-expression.
1. Introduction
About 10 distinct potassium (K+) channels participate in the re-
polarization of cardiac action potentials (APs) [1]. However, how they
map into the net AP repolarizing current is complicated; in the ven-
tricles, the rapid and slow delayed rectiﬁer K+ currents (IKr and IKs)
inﬂuence AP repolarization over plateau voltages, whilst the inward
rectiﬁer K+ current (IK1) is involved in both setting the resting potential
and mediating the ﬁnal repolarization phase of the AP [1,2]. The
transient outward K+ current, Ito, contributes to phase 1 repolarization
but will also aﬀect later repolarization phases of the AP by modifying
the time- and voltage-dependent recruitment of other K+ currents (such
as IKr, IKs) as well as L-type Ca2+ current (ICa,L) [2]. In addition, Ito will
aﬀect NCX current via eﬀects on ICa,L dependent Ca2+ release as well as
via Ca-dependent inactivation of ICa,L [3–5]. Native Ito has components
with fast and slow recovery kinetics (Ito,f and Ito,s respectively) and
KCND2 (Kv4.2) and KCND3 (Kv4.3) underlie Ito,f, while KCNA4 (Kv1.4)
is responsible for Ito,s [2,6].
The normal physiological behaviour of many cardiac K+ channels
appears to require both pore-forming (α) and accessory (β) subunits to
be co-expressed and associated [7]. Native Ito,f channels require inter-
actions between α-subunits and K+ Channel interacting Protein 2
(KChIP2) β-subunits, but other proteins such as DPP6 and members of
the KCNE family may also modulate the current [6,8–11]. Two splice
variants of KChIP2 (called KChIP2L and KChIP2S) were discovered by
RT-PCR cloning [12] and the shorter form KChIP2S (also called KChIP2
isoform-1 or KChIP2.1) was identiﬁed as the predominant isoform in
human heart [13]. Additional expression cloning from human revealed
another splice variant of KChIP2, KChIP 2.2 which was 32 amino acids
shorter than KChIP2.1 and which, like KChIP 2.1, also increased Kv4.2
channel cell-surface expression and slowed inactivation [14] (for a re-
view of KChIP isoforms and nomenclature see Table 1 in [15]).
KChIP2.1 and KChIP2.2 are produced by alternative splicing from the
KChIP2 gene removing exons 3 and 2+3 to produce isoforms coding of
252 and 220 amino acids respectively [16].
The AP depolarization also activates IKr which plays a key role in
determining action potential duration [17]. Recordings at physiological
temperature from recombinant hERG channels (Kv11.1) expressed in
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mammalian cells closely approximate native IKr [18]. The accessory
subunits of native IKr channels have been a matter of some debate as
hERG can co-assemble with both KCNE1 and KCNE2 and clinically
observed mutations in these subunits can inﬂuence hERG current and
the channel’s pharmacological sensitivity [19–21]. The potassium
channel regulatory protein KCR1 has also been shown experimentally
to inﬂuence drug sensitivity of hERG channels [22] and the possible
interaction with other K+ channel regulatory units is uncertain. Recent
data suggest that hERG channel current magnitude is inﬂuenced by
Kv4.3 co-expression [23], but no such information exists for Ito beta
subunits. KChIP2 has recently been identiﬁed to act as a core tran-
scriptional regulator of cardiac excitability [24]. That KChIP may also
eﬀect other K channels (such as hERG/Kv11.1) is suggested by the
observation that KChIP knockdown in myocytes (from guinea pig) that
do not express Ito increases action potential duration [25]. While this
did not seem to be associated with a detectable change in IKr, the nat-
ural low level of expression of KChIP2 in guinea pig leaves open the
possibility of interactions at higher levels of expression. The pro-
miscuous nature of KChIP2 interactions is further underscored by data
demonstrating altered L-type Ca current magnitude in murine myocytes
lacking KChiP2 and a direct interaction between KChiP2 and Cav1.2
[26]. Such interactions could have important ramiﬁcations for drug
design in the future and need evaluation.
Small molecule activators of cardiac K+ channels that both increase
repolarizing current and prolong post-repolarisation refractoriness have
the potential to oﬀer novel antiarrhythmic actions [27]. Furthermore,
activators of Ito may restore early repolarization and inhibit dyssyn-
chronous Ca2+ release that occurs consequent to loss of the early re-
polarization notch of the AP in heart failure [4,5]. A prototypical Ito
activator, NS5806, has been shown to enhance native ventricular Ito in
dog and rabbit and it also increases recombinant Kv4.2 and 4.3 currents
[28–31]. The agonist eﬀect of NS5806 on Kv4.x channels requires the
presence of KChIP2.1 [32]. Canine atrial Ito is augmented by NS5806 to
a much smaller extent than ventricle, whilst rabbit atrial Ito is
paradoxically inhibited by the compound [31,33]. NS5806 also has an
oﬀ-target eﬀect of atrial-selective Na channel inhibition [31,33], and a
related compound, NS3623, has been reported to be a dual activator of
IKr and Ito and to increase repolarization reserve in cellular and multi-
cellular canine preparations[29]. NS3623 was originally described as a
chloride channel inhibitor [34] but it also activates hERG/IKr [35].
Paradoxically, NS3623 had no signiﬁcant eﬀect on Kv4.3 channels ex-
pressed in Xenopus oocytes at 30 µM [35], despite eﬀects on epicardial
AP notch, J wave amplitude and increasing Ito (and IKr) in canine pre-
parations (at 1–5 µM) [29]. These conﬂicting results led us to hy-
pothesize that the lack of sensitivity of Kv4.3 to NS3623 could be due to
the absence of KChIP2/DPP6 in the aforementioned oocyte experiments
[35] or that the augmentation of Ito [29] might be due to some other
mechanism that aﬀects Kv4.3 current density rather than an eﬀect on
the channel (and/or Kv4.3 β-subunits) per se.
The present study had three aims: ﬁrst, to compare the gating
properties of Kv4.3 co-expressed with either KChIP2.1 or KChIP2.2 with
and without DPP6. Second, to examine the eﬀects of NS3623 on Kv4.3
and hERG, in both the presence and absence of KChIP2 and DPP6 in a
mammalian cell expression system. Finally, to examine the possibility
that KChIP2.1, KChIP2.2 and DPP6 expression may aﬀect Kv11.1
(hERG) by transfecting each β-subunit (along with GFP protein as a
reporter) in a stably transfected mammalian (HEK 293) cell line which
expresses hERG channels.
2. Methods
2.1. DNA constructs
The cDNA constructs coding for human short Kv4.3 isoform 1 pre-
cursor (KCND3 gene cloned in pcDNA3, NCBI reference sequence
NM_172198.2) [36] and KChIP2 variant 2 (KCNIP2 gene cloned in
pcDNA3, NCBI reference sequence NM_173195.2) [14], herein desig-
nated as KChIP2.2 (220 amino acid long) were kindly provided by
Table 1
Comparison of biophysical parameters for HEK 293 cells expressing recombinant Kv4.3 alone or in the presence of KChIP2 isoforms and/or DPP6.
Kv4.3 KChIP2.2 KChIP2.1 KChIP2.2/DPP6 KChIP2.1/DPP6
IpA/pF
@ +40mV#
453 ± 62 (n= 33) 780 ± 87 (n= 16)§ 1044 ± 88 (n= 13)§† 873 ± 79
(n=14)§
828 ± 107
(n= 15)§
Recovery τrec (ms)# 46.10 ± 6.19 (n= 18) 5.88 ± 0.55 (n= 12)§ 11.99 ± 1.8 (n= 13)§ 5.30 ± 0.47 (n= 13)§ 8.21 ± 1.03
(n= 14)§
Decay τf (ms)# 11.16 ± 0.89 (n= 23)‡ 13.82 ± 0.74 (n= 12)‡ 21.24 ± 2.88 (n= 12) 9.17 ± 0.59 (n= 12)‡ 10.52 ± 1.10 (n= 13)‡
Decay τs (ms)# 84.7 ± 4.9 (n= 23) 132.8 ± 17.3 (n= 12)§ 146.4 ± 23.9 (n= 12)§ 82.6 ± 4.1
(n=12)†
71.2 ± 6.9
(n= 13)†‡
IpA/pF +NS3623 @ +40mV# 567 ± 87 (n= 16) 796 ± 145 (n= 9) 1142 ± 124 (n= 10)§ 948 ± 90
(n=12)§
917 ± 95
(n= 10)§
Recovery τrec (ms) +NS3623# 146.2 ± 18.1 (n= 14) 21.3 ± 3.8 (n= 9)§ 30.9 ± 3.4 (n=10)§ 19.4 ± 5.1
(n=8)§
31.4 ± 5.4
(n= 9)§
Decay τf (ms) +NS3623# 9.85 ± 0.69 (n=14) 19.37 ± 1.03 (n= 9)§,‡ 26.8 ± 3.42 (n= 10)§ 14.54 ± 0.97 (n= 12)‡ 14.83 ± 1.13 (n= 11)‡
Decay τs (ms) +NS3623 65.1 ± 2.53 (n=14) 71.3 ± 7.1 (n= 9) 86.8 ± 9.6 (n=10)§ 60.3 ± 4.2
(n=12)‡
67.4 ± 4.7
(n= 11)
% Change
(IpA/pF)
144 ± 5%
P= .0001
131 ± 2%
P= .0078
132 ± 2%
P= .002
141 ± 3%
P= .0002
129 ± 3%
P= .002
Fold change
(τrec)*
3.83 ± 0.57
P= .0001
4.68 ± 0.39
P= .0039
3.84 ± 0.47
P= .0002
3.04 ± 0.65
P= .0078
3.72 ± 0.40
P= .0039
% Change
(τf)*#
92 ± 5%
P= .11
135 ± 6%§
P= .0078
132 ± 8%§
P= .0098
159 ± 6%§
P < .0005
156 ± 15%§
P= .001
% Change (τs)* 77 ± 3%
P= .0001
51 ± 8%
P= .0039
69 ± 12%
P= .054
73 ± 4%
P= .001
98 ± 9%†‡
P= .557
Fold change (AUC)#¥ 1.27 ± 0.06 1.50 ± 0.07
P=0.769
1.45 ± 0.11
P=0.865
2.09 ± 0.22
P=0.0005
2.26 ± 0.18
P < 0.0001
# One-way ANOVA.
* Wilcoxon matched-paired signed rank test.
§ Compared to Kv4.3.
† Compared to KChIP2.2.
‡ Compared to +KChIP2.1.
¥ P values shown are against the extent of increase in current integral (AUC) due to NS3623 compared to Kv4.3 alone.
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Professor Robert Bähring (Universitätsklinikum Hamburg-Eppendorf,
Hamburg, Germany). The cDNA constructs coding for human DPP6
variant 1 (DPP6 gene cloned in pcDNA3.1+, NCBI reference sequence
NM_130797.3) and KChIP2.1 (KCNIP2 gene cloned in pCMV-3Tag-1a,
NCBI reference sequence NM_173192.2) were synthesized and se-
quenced by GenScript (GenScript, Piscataway, New Jersey, USA).
2.2. Cell culture and transfection
HEK 293 cells (European Collection of Cell Cultures, Porton Down,
UK) transfected with Kv4.3 or a stable HEK 293 cell line expressing
wild-type (WT) hERG (Kv11.1) channels (kindly provided by Professor
Craig January) [37] were used. Additional K+ channel β–subunits were
also transfected into the cells (as described below). Cells were main-
tained at 37 °C in a humidity controlled incubator with 5% CO2 atmo-
sphere and cultured in Dulbecco’s modiﬁed Eagle’s medium (Thermo
Fisher Scientiﬁc, Life technologies division, Paisley, UK) supplemented
with 10% (v/v) heat inactivated fetal bovine serum (Thermo Fisher
Scientiﬁc, Life Technologies division, Paisley, UK), 1% (v/v) non-es-
sential amino acids (Thermo Fisher Scientiﬁc, Life Technologies divi-
sion, Paisley, UK) and 50 μg/mL Gentamicin (Merck KGaA, Darmstadt,
Germany). In the case of hERG-expressing HEK 293 cells, the medium
was further supplemented with 400 μg/ml G418 selection antibiotic
(Thermo Fisher Scientiﬁc, Life technologies division, Paisley, UK). Prior
to transfection, cells were plated for 48 h onto 12-well plates using a
non-enzymatic agent (Merck KGaA, Darmstadt, Germany) before
transfection. Transfection reactions were prepared using OPTI-MEM® I
(Thermo Fisher Scientiﬁc, Life Technologies division, Paisley, UK). For
Kv4.3 experiments 0.3 μg of DNA was transfected along with either 1 μg
of a GFP construct (control) or KChIP2.1/2.2. In experiments where a
KChIP2 isoform and human DPP6 were co-transfected, 0.8 μg of each
DNA was transfected and compared to a “control” condition, in which
1.6 μg of GFP alone was transfected. For hERG experiments, a matching
concentration of GFP DNA was used, in order to have an equivalent
DNA concentration across all conditions. Lipofectamine™ 2000 trans-
fection agent (Thermo Fisher Scientiﬁc, Life Technologies division,
Paisley, UK) was used at a 2:1 ratio with DNA. The culture medium was
replaced 5 h after transfection. After 24 h, cells were collected and re-
plated onto 13mm round glass coverslips, pre-treated for 4 h with
200 μg/mL Poly-D-Lysine (Merck KGaA, Darmstadt, Germany). Patch-
Clamp recordings started 3 h after plating.
2.3. Reagents and solutions
The compound NS3623 was purchased from Santa Cruz
Biotechnology Inc. (Dallas, Texas, USA) and dissolved in DMSO to a
ﬁnal concentration of 10mmol/L. Individual aliquots were frozen at
−20 °C and thawed for use on the day of the experiment. The DMSO
stock (Merck KGaA, Darmstadt, Germany) was diluted to a ﬁnal con-
centration of 0.1% in extracellular solution to give an 10 μmol/L
NS3623 solution, as used previously [29]. All reagents to prepare so-
lutions were purchased from Merck KGaA (Darmstadt, Germany) or
Sigma-Aldrich (Poole, Dorset, UK). The extracellular solution contained
(in mmol/L): 138 NaCl, 4 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 10 Glucose
and 0.33 NaH2PO4 (pH adjusted to 7.4 with concentrated NaOH). The
intracellular solution used for Kv4.3 (Ito current) recordings was based
on that from previous study of Kv4.3 [32]. The patch pipette solution
contained in mmol/L: 90 KAspartate, 30 KCl, 10 NaCl, 1 MgCl2, 5
EGTA, 5 MgATP, 10 HEPES, 5.5 Glucose (pH adjusted to 7.3 with KOH).
The intracellular solution for hERG (IKr current) recordings was similar
to that used in prior studies from our laboratory [38–40], containing in
mmol/L: 130 KCl, 1 MgCl2, 5 EGTA, 5 MgATP, 10 HEPES (pH adjusted
to 7.3 with KOH).
2.4. Electrophysiology and data analysis
Patch pipettes (2.5–3MΩ resistance) were fabricated from bor-
osilicate glass capillaries (Friedrich & Dimmonck, Millville, New Jersey,
USA) using a P-87 puller (Sutter Instruments, Novato, California, USA).
Data were acquired and recorded with Clampex 10.3 software using an
Axopatch 200 ampliﬁer and Axon Digidata® 1322A (Molecular Devices,
Sunnyvale, California, USA). Data were digitized at 20 kHz during all
voltage protocols and a bandwidth of 2 kHz was set on the ampliﬁer.
For whole-cell recordings, cells were continuously perfused with ex-
tracellular solution at 33 ± 1 °C. Access resistance (Ra) was always
below 5 MΩ and series resistance was typically compensated by∼40%.
Voltage protocols are described in the “Results” section. Patch-Clamp
recordings were analysed using Clampﬁt 10.3 (Molecular devices,
Sunnyvale, USA). Statistics and graphs were prepared using Excel
Professional Plus 2013 (Microsoft Corporation, Redmond, Washington,
USA) and Prism 7 for Windows (GraphPad Software, La Jolla,
California, USA).
2.5. Statistics
Statistical signiﬁcance was assessed by applying a non-parametric
test for comparing two diﬀerent conditions within a group (Wilcoxon
matched-paired signed rank test) and analysis of variance or one-way
ANOVA (Tukey post-hoc analysis) when comparing three or more
groups. Two-way ANOVA test (Sidak post-hoc test) was used when
multiple comparison between diﬀerent groups was necessary. In all
cases, a p value of less than .05 was required for statistical conﬁdence.
Values are expressed as mean ± standard error of the mean (SEM).
3. Results
3.1. Eﬀect of KChIP2 expression on Kv4.3 biophysical properties
Initial experiments examined the eﬀect of both KChIP2.2 and
KChIP2.1 on Kv4.3. The voltage protocol involved square voltage steps
from−60 to +40mV (Vm) in 10mV increments from a holding voltage
(Vh) of −80mV, as illustrated in the inset to the top panel of Fig. 1A.
Co-expression of Kv4.3 with either KChIP2 isoform produced a robust
increase in outward currents when compared to Kv4.3 alone (Fig. 1A
and B). For Kv4.3, current density at +40mV was 490 ± 108 pA/pF
(n= 7), which increased to 833 ± 107 pA/pF (n=12) and
1043 ± 88 pA/pF (n=13) for cells expressing KChIP2.2 and
KChIP2.1, respectively (Fig. 1B and Table 1). In addition, we evaluated
the eﬀect of expressing both KChIP2 isoforms with human DPP6 as the
presence of both accessory subunits may be necessary to recapitulate
native Ito [9]. The presence of DPP6 reduced the augmentation of Kv4.3
current produced by KChIP2.1, resulting in both KChIP isoforms having
(essentially) the same agonistic eﬀect on Kv4.3 in the presence of DPP6
as shown in Fig. 1C and detailed in Table 1.
Fitting a bi-exponential decay function to the Ito inactivation time
course showed that expression of KChIP2.1 consistently increased both
the fast and slow time constants compared to Kv4.3 alone (Fig. 1D,
Table 1). Values for tau fast were 11.16 ± 0.89ms (Kv4.3; n= 23) vs
21.24 ± 2.88ms (KChIP2.1; n= 12) (One-way ANOVA; p < .001),
while slow time constant values were 84.7 ± 4.9ms (n=23) vs
146.4 ± 23.9 ms (n=12) (One-way ANOVA; p < .01). Interestingly,
co-expression of KChIP2.2 increased the Kv4.3 slow time constant to
132.8 ± 17.3 ms (n=12; One-way ANOVA p < .05), but not the fast
component (Fig. 1D, Table 1). Finally, addition of DPP6 with KChIP2
isoforms opposed the changes in Kv4.3 inactivation due to KChIP2
expression alone (Fig. 1D, Table 1).
The time-course of recovery of Ito from inactivation was measured
using a protocol consisting of two square voltage pulses (500ms and
200ms long, respectively) to +40mV with varying interpulse intervals,
Δt (10–2000ms) as illustrated in the inset to Fig. 1E. A plot of the
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fraction of recovered current against inter-pulse interval was generated
and ﬁtted with a mono-exponential function whose time constant (τrec)
characterized the rate of recovery. The expression of KChIP2 isoforms
decreased Kv4.3 τrec from 46.10 ± 6.19ms (n=18) to
5.88 ± 0.55ms (p < .0001, n=12) and 11.99 ± 1.87ms
(p < .0001, n= 13) in the presence of KChIP2.2 and KChIP2.1, re-
spectively (Fig. 1E). Co-expression of DPP6 with KChIP2.1/2.2 isoforms
had only small eﬀects on τrec compared to KChIP alone (Fig. 1F,
Table 1).
3.2. NS3623 modulates the gating properties of the Kv4.3/KChIP2/DPP6
protein complex
Recently, 5 μmol/L NS3623 has been reported to increase native Ito
in canine ventricular myocytes at membrane potentials above +10mV
[29]. In addition, recovery from inactivation was shown to be slightly
faster in the presence of NS3623. We therefore examined the eﬀect of
10 μmol/L NS3623 on Kv4.3 currents at +30mV alone, in the presence
of KChIP2 isoforms with and without DPP6. Representative current
traces are shown in Fig. 2A. In all cases, application of NS3623 resulted
in an increase in current magnitude, but to an extent that depended on
isoform co-expression. The greatest increase in current was seen in cells
expressing Kv4.3 alone (x1.44 ± 0.05, p= .0001 n=16) and co-ex-
pression with KChIP2.1/DPP6 resulted in a signiﬁcantly reduced
agonism (Table 1 and Fig. 2B). Application of NS3623 in the presence of
either KChIP2.2 or KChIP2.1 led to a ∼35% increase in the Kv4.3
current fast inactivation time constant (Fig. 2C, Table 1). Without these
subunits, the time constant was not detectably altered by NS3623
(p= .15, Table 1). When DPP6 was also expressed with KChIP2.1/2.2,
the Kv4.3 current fast inactivation time constant was further increased
(p < .0005 and p= .001 in KChIP2.2 and KChIP2.1, respectively). The
opposite eﬀect was observed for slow time constants (Table 1). The
KChIP2-mediated increase in time constants was generally reversed by
10 μmol/L NS3623 application (Table 1). Furthermore, values from all
conditions (including Kv4.3 alone), with the exception of KChIP2.1
(with and without DPP6 co-expression), showed a signiﬁcant accel-
eration of the slow component of inactivation (paired t-test; p < .05,
Table 1). Nevertheless, the overall eﬀect of NS32523 was greatest in the
presence KChIP2.x co-expressed with DPP6, as shown by the change in
current integral (AUC Table 1).
Recovery of Ito from inactivation was slowed by NS3623 in all our
Kv4.3 expression conditions (i.e. KChIP2.1/2.2 +/− DPP6) by a factor
of 3–4 (see Fig. 2D–F; Table 1). However, the current from cells ex-
pressing accessory subunits still recovered much faster than that from
cells expressing Kv4.3 alone (Fig. 2D and E; Table 1).
3.3. KChIP2.1/2.2 and DPP6 do not aﬀect hERG current density or
voltage-dependence
The possible eﬀects of KChIP2.1/2.2 and DPP6 on hERG current
(IhERG)) were evaluated with a standard hERG voltage clamp protocol
(i.e. a voltage step from a Vh of−80 to +20mV to activate the current
followed by a repolarizing step to −40mV – see Fig. 3A). Both end-
pulse and tail currents showed the expected electrophysiological char-
acteristics, (Fig. 3B and C). Current densities in the absence of any
accessory subunit were 51.6 ± 4.5 pA/pF (n=32) and 100.4 ± 7.5
(n= 32) for IEnd Pulse and Itail, respectively and current magnitudes
were not changed by co-expression with KChIP2.1/2.2 or DPP6
(Table 2). We also examined the normalised voltage dependence of
IhERG when applying a 2-s-long voltage steps from a Vh of −80mV to
potentials between−40 and +60mV. Each test pulse was followed by
a repolarization step to−40mV (Fig. 3D and Table 2). As is typical for
IhERG, current increased with progressive depolarization up to 0mV
(e.g. [37]). Further depolarization to test potentials above +10 resulted
in current decline, as indicated by the region of negative slope on the
end-pulse I-V relation (Fig. 3E). Tail current activation upon
Fig. 1. Modulation of Kv4.3-mediated currents by accessory subunits transiently expressed in HEK 293 cells. (A) Representative traces showing a family of transient outward currents
mediated by Kv4.3 and when co-expressed with KChIP2.x isoforms. Inset shows voltage protocol used to elicit these currents. (B) Current to voltage relation from Kv4.3 and KChIP2
isoforms. (C) Current to voltage relation from Kv4.3 co-expressed with KChIP2.x isoforms and DPP6. (D) Bi-exponential functions were ﬁtted to current decays, and fast time constant at
+40mV were analysed and compared across all groups. (E) Time-dependent recovery from inactivation. Normalised tail peak current amplitudes were recorded at +40mV and plotted
as a function of the inter-pulse interval (Δt) (protocol illustrated in the inset and described in the ‘Results’ section). A single exponential growth curve was ﬁtted to each condition. Panel E
compares the eﬀect of diﬀerent KChIP2.x isoforms, while panel F shows results for KChIP2.x/DPP6 co-expression. Numbers of replicates for the diﬀerent groups and protocols are given in
Table 1.
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repolarization to −40mV followed a sigmoidal activation pattern
which could be ﬁtted by a Boltzmann function (Fig. 3F). Examination of
the Boltzmann half-activation voltage (V1/2) and slope parameters
showed essentially no change with KChIP2.1/2.2 and DPP6 (Table 2).
3.4. Eﬀect of KChIP2.1/2.2 and DPP6 on IhERG rectiﬁcation and
deactivation time course
The eﬀect of KChIP2.1/2.2 and DPP6 co-expression on IhERG recti-
ﬁcation properties and deactivation time course was examined using
Fig. 2. Eﬀect of NS3623 on Kv4.3 co-expressed with diﬀerent combinations of accessory subunits. (A) Representative traces showing NS3623-mediated activation of Kv4.3 compared to
Kv4.3/KChIP2.1/DPP6. (B) Fold increase in Kv4.3 outward currents upon application of 10 μM NS3623 measured at +30mV. *P < .05; signiﬁcant diﬀerent between Kv4.3 and Kv4.3/
KChIP2.1/DPP6 activation rate. (C) Current decay was ﬁtted to a bi-exponential function in the presence of NS3623 and the fast component of inactivation at +30mV was compared in
all groups; *P < .05, **P < .01, ***P < .001. (D) Time-dependent recovery from inactivation in the presence of NS3623 (same voltage protocol as used in Fig. 1). Curves show a single
exponential function ﬁt to the recovery from inactivation with KChiP2.x co-expression. In panel E, Kv4.3 recovery kinetics are shown when both KChIP2.x isoforms and DPP6 are co-
expressed in the presence of NS3623. (F) Histogram showing the fold increase in time constants after 10 μM NS3623 application. Numbers of replicates for the diﬀerent groups and
protocols are given in Table 1.
Fig. 3. Eﬀect of KChIP2.x and DPP6 on IhERG. (A) Representative trace from a cell expressing hERG alone showing outward currents (IhERG) elicited by the voltage protocol shown below
the recording. (B) Mean current density values recorded at the end of the +20mV voltage segment (lower arrow in panel A) and, (C) from tail currents after repolarization to +40mV
(higher arrow from panel A) for all conditions. Tail current amplitude was measured between peak outward tail and the brief (50ms) prepulse to−40mV that preceded the +20mV step.
(D) Example of a representative family of currents from a cell expressing hERG alone elicited by application of the voltage protocol shown below. For clarity, only the responses to
selected voltages are depicted. (E) Normalized I-V relation plotted in function of the voltage for end pulse mean currents recorded at +20mV for all groups studied (Two-way ANOVA;
P > .41 for each comparison). Symbol legend is in panel F. (F) Normalized I-V relation from mean tail currents recorded at +40mV (Two-way ANOVA; P > .49 for each comparison. All
currents were normalised against the largest current for the region from the I-V protocol being analysed. Numbers of replicates for the diﬀerent groups and protocols are given in Table 2.
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the voltage protocol shown in Fig. 4Ai and test pulses were applied at
12 s intervals to ensure full recovery between pulses. Fig. 4Aii shows
representative currents elicited by this protocol and Fig. 4B shows the
resulting I-V relation. IhERG exhibited a voltage-dependence that was
very similar to previous studies (e.g. [37,41]). Accessory subunit ex-
pression had no measurable eﬀect on the resulting currents (Fig. 4B). In
all cases, the fully activated I-V relation was maximal with a repolar-
ization step to ∼30mV. Likewise, all groups showed a similar reversal
Table 2
Summary of gating properties of recombinant hERG channels alone or in the presence of accessory subunits.
hERG hERG/KChIP2.2 hERG/KChIP2.1 hERG/DPP6
IEnd Pulse (pA/pF)# 51.5 ± 4.5 (n= 32) 55.9 ± 6.7
(n= 21)
47.3 ± 4.5
(n= 28)
41.1 ± 3.3
(n= 24)
ITail (pA/pF)# 100 ± 7
(n= 32)
118 ± 13
(n= 21)
90 ± 8
(n= 27)
94 ± 9 (n= 26)
I-V relation tail V1/2 (mV)# −21.9 ± 1.8
(n= 13)
−23.0 ± 2.5
(n= 6)
−22.9 ± 6.3
(n= 9)
−21.0 ± 2.3
(n= 15)
I-V relation tail κ (mV)# 6.13 ± 0.25
(n= 13)
5.99 ± 0.49
(n= 6)
5.94 ± 0.60
(n= 9)
5.9 ± 0.2
(n= 15)
Activation τact (ms)# 64.1 ± 7.6
(n= 12)
41.1 ± 5.3*
(n= 9)
66.8 ± 11.2
(n= 10)
68.9 ± 20.9
(n= 8)
Reversal Erev (mV)# −84.0 ± 0.9
(n= 9)
−84.7 ± 0.5
(n= 5)
−84.4 ± 0.6
(n= 7)
−85.5 ± 0.7
(n= 6)
Recovery τrec (ms)# 4.29 ± 0.43
(n= 12)
3.48 ± 0.22
(n= 10)
5.22 ± 0.38
(n= 13)†
4.29 ± 0.47
(n= 10)
Deactivation τfast (ms)# 126 ± 11
(n= 9)
140 ± 21
(n= 5)
151 ± 23
(n= 6)
148 ± 13
(n= 6)
Deactivation τslow (ms)# 692 ± 37
(n= 9)
852 ± 162
(n= 5)
764 ± 91
(n= 6)
792 ± 74
(n= 6)
IEnd Pulse (pA/pF) Control# 43.9 ± 6.8
(n= 12)
39.6 ± 5.8
(n= 11)
36.0 ± 6.8
(n= 11)
48.1 ± 10.8
(n= 7)
IEnd Pulse (pA/pF) +NS3623# 60.8 ± 10.8
(n= 12)
52.9 ± 8.9
(n= 11)
53.0 ± 11.5
(n= 11)
62.7 ± 13.4
(n= 7)
% Change
IEnd Pulse (pA/pF)*
135 ± 4%
P= .0005
130 ± 3%
P= .001
145 ± 6%
P= .001
131 ± 6%
P= .015
ITail (pA/pF) Control# 99.5 ± 13.5
(n= 12)
100.3 ± 11.9
(n= 11)
83.3 ± 9.1
(n= 11)
112.5 ± 22.5
(n= 7)
ITail (pA/pF) +NS3623# 121.1 ± 16.8
(n= 12)
118.3 ± 13.5
(n= 11)
108.9 ± 11.5
(n= 11)
136.1 ± 28.7
(n= 7)
% Change
ITail (pA/pF)*
122 ± 3%
P= .001
119 ± 2.3%
P= .001
131 ± 3%
P= .001
124 ± 4%
P= .0156
§Compared to +KChIP2.2.
# One-way ANOVA.
* Wilcoxon matched-paired signed rank test.
† Comparedto hERG/KChIP2.2.
Fig. 4. Fully activated I-V relations and deactivation time constants from cells expressing hERG and KChIP2.x or DPP cytosolic proteins. (Ai) Shows the voltage protocol used to elicit
typical hERG-mediated currents as shown in (Aii). (B) Plot of normalized fully activated I-V relationships for all conditions studied (n values are shown in the graph legend). (C) Graph
showing fast and (D) slow time constants measured after ﬁtting IhERG current deactivation to a bi-exponential equation at each repolarization voltage. Numbers of replicates for the
diﬀerent groups and protocols are given in Table 2.
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potential around −85mV (Table 2) with no signiﬁcant changes de-
tected.
The deactivation time-course was calculated from the tail currents
(Itails) at each repolarization potential for each cell by ﬁtting a bi-ex-
ponential function, giving fast (τfast) and slow (τslow) components
(Fig. 4D, left and right panels and Table 2). Similar to the lack of eﬀect
of subunit co-expression on the fully activated I-V relation, both com-
ponents of deactivation were unaﬀected by the addition of KChIP2.1/
2.2 or DPP6.
3.5. KChIP2.1/2.2 and DPP6 eﬀects on IhERG activation and inactivation
recovery
Activation time course of IhERG was evaluated using an “envelope of
tails” protocol [37,42,43]. The protocol consisted of a variable duration
pre-pulse to +20mV (from 10 to 3000ms) followed by a repolarizing
step to −40mV to de-activate IhERG and produce a tail current (Itail).
Itail amplitudes were then ﬁtted by a monoexponential function to give
time constants for activation which were compared across diﬀerent
expression conditions (Fig. 5A and B and Table 2). Neither co-expres-
sion with KChIP2.1 nor DPP6 altered the activation time-course
(p= .99 for both groups, One-way ANOVA). However, KChIP2.2 co-
expression resulted in a ∼35% increase in the rate of IhERG activation
(p= .049, One-way ANOVA) (Fig. 5B and Table 2).
To examine the time dependence of recovery from inactivation we
used a 2 s long depolarizing step to +40 to activate IhERG current
(during which a proportion of hERG channels inactivate), followed by a
variable length repolarization step to −40mV (between 2 and 20ms
long) to allow the channels to recover from inactivation. This was fol-
lowed by a 20ms test step to +40mV to probe the extent of recovery
from inactivation. Currents were normalized to the maximal current
seen during the second +40mV steps (Fig. 5C and Table 2). No sig-
niﬁcant diﬀerences in the rate of IhERG recovery were observed, al-
though KChIP2.2 co-expression resulted in a signiﬁcantly faster re-
covery time-constant compared to KChIP2.1 (Fig. 5D and Table 2. One-
Way ANOVA, p= .016).
3.6. Eﬀect of KChIP2 isoform and DPP6 expression on IhERG activation
during the ventricular AP
Although KChIP2.1/2.2/DPP6 co-expression had only small eﬀects
on the individual kinetic parameters of IhERG, the acceleration of acti-
vation by (for example) KChIP2.2 and other kinetic interactions during
the dynamic AP might produce some summative eﬀect. We therefore
examined potential modulation of IhERG by KChIP2.1/2.2/DPP6 acces-
sory subunits under AP clamp as the most physiological stimulus, using
a digitised human ventricular AP waveform as the voltage command
[38,40,44]. The AP waveform as well as an exemplar IhERG record from
a cell expressing only hERG are shown in Fig. 6A and Table 2. Con-
sistent with prior studies, IhERG current slowly increased during the
plateau phase before quickly increasing in amplitude once the re-
polarization phase of the action potential started, with a maximal peak
at ∼−40mV [38,44]. Current dramatically declined during terminal
repolarization. As expected from the above data, only small diﬀerences
on the activation proﬁle are seen in the normalized instantaneous I-V
relation for all conditions (Fig. 6B cf. Table 2), speciﬁcally at voltages
more depolarized than −40mV. Maximal currents occurred late in
repolarization in all conditions, with a mean membrane potential of
−35.58 ± 0.94mV (n= 11) in hERG-only expressing cells. The vol-
tages in the other groups were: −32.10 ± 0.89mV (hERG/KChIP2.2;
n= 7),−35.63 ± 2.68 (hERG/KChIP2.1; n= 7) and−35.91 ± 1.11
(hERG/DPP6; n=8). No signiﬁcant changes due to KChIP2.1/2.2/
DPP6 co-expression were detected (One-Way ANOVA, p= .27).
3.7. Eﬀect of KChIP2 and DPP6 in the NS3623-mediated IhERG activation
In addition to the eﬀect of NS3623 on Ito in ventricular cardio-
myocytes, this compound also activates hERG ion channels in ex vivo
preparations [29,35,45]. To conﬁrm the activity of NS3623 against
IhERG and to explore the involvement of either KChIP2.1/2.2 isoforms
and DPP6 in the compound-mediated response, we used our “standard”
IhERG voltage step protocol (Fig. 3A) before and after adding 10 μmol/L
NS3623. Representative IhERG traces in control (black line) and with
Fig. 5. hERG-mediated time dependence from
activation and recovery from inactivation. (A)
Normalized activation time-course measured at
−40mV when applying an envelope of tails
protocol for hERG channels as shown in the inset.
(B) Experimental values for each cell were ﬁtted
to a mono-exponential equation and activation
time constants were compared for all conditions
tested. (C) Normalized mean recovery from in-
activation data was plotted as a function of the
fraction of time at −40mV (2–20ms). The pro-
tocol is shown as an inset. (D) As in B, peak cur-
rents at each time point for each recorded cell
were ﬁtted to a mono-exponential equation from
which time constants were extracted and com-
pared. Numbers of replicates for the diﬀerent
groups and protocols are given in Table 2.
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10 μmol/L NS3623 (dotted line) are shown in Fig. 7A and a plot of IhERG
tail amplitudes (at −40mV) over time is shown in Fig. 7B. The results
show that IhERG is quickly, and reversibly, activated by NS3623. An
increase in IhERG in response to NS3623 was always observed when
KChIP2.1/2.2 and DPP6 were co-expressed and the degree enhance-
ment of IhERG was independent of KChIP2.x and DPP6 co-expression
(see Fig. 7C and D, Table 2).
4. Discussion
To our knowledge, this is the ﬁrst study to investigate a potential
modulatory role of the accessory subunits KChIP2.1, KChIP2.2 and
DPP6 on recombinant hERG channels and to evaluate the dual po-
tassium channel opener NS3623 on recombinant Kv4.3 channels. In
addition, we have examined the eﬀect of the 220 amino acid long
isoform KChIP2.2 as well as KChIP2.1 on Kv4.3 and its response to
NS3623, both of which are expressed in human cardiac tissue [14,46].
It is important to point out that we have used expression of GFP protein
as a reporter to identify cells expressing the ancillary subunits of in-
terest. Although this approach does not guarantee that all constructs are
expressed within the same cells, it was reassuring that the current
density-voltage (I-V) plots in Fig. 1B and C showed distinct patterns
depending on whether KChIP2.1 or KChIP2.2 was co-transfected with
Kv4.3 or with the presence/absence of DPP6. Furthermore, for Kv4.3
experiments, we have used substantial replicate ‘n’ numbers (see Figs. 1
and 2), so we are conﬁdent that our measurements should reﬂect suc-
cessful transfection.
4.1. KChIP2.1, KChIP2.2 and DPP6 eﬀects on Kv4.3 electrophysiology
Expression of both KChIP2.1 and KChIP2.2 resulted in a larger
Kv4.3-mediated outward current (giving a ∼2.3 and ∼1.7-fold larger
current at +40mV respectively) than Kv4.3 alone. Qualitatively, our
results are in reasonable accord with previous studies assessing
KChIP2.1 and Kv4.3 expressed in HEK 293 cells [46], CHO cells [47]
and Xenopus oocytes [48,49], although our data show that KChIP2.2
increases current magnitude more weakly than KChIP2.1 (p= .0033 at
+40mV, Two-way ANOVA). Importantly, addition of DPP6 reduced
the diﬀerence in current density produced by the KChIP2.1/2.2 iso-
forms by reducing the current density which was increased by KChIP2.1
Fig. 6. Eﬀect of KChIP2 and DPP6 on hERG-acti-
vated currents elicited during application of a
ventricular AP clamp. (A) Plot of ventricular AP
command waveform and the associated normal-
ised IhERG activation proﬁle from a cell expressing
hERG alone. Currents were normalised against the
largest current. (B) Mean normalised in-
stantaneous I-V relationship for all conditions
during AP repolarization. Currents were normal-
ised to the largest elicited during the protocol.
Numbers of replicates are given in the inset
within the plot.
Fig. 7. IhERG activation by 10 μM NS3623 in the
absence/presence of KChIP2 or DPP6. (A)
Representative traces from IhERG both in the ab-
sence (solid line) and presence of NS3623 (dotted
line) from a cell expressing hERG alone. (B)
Example of a tail current peak response proﬁle.
Each point represents application of a voltage
protocol such as the one shown in A. The red bar
represents the length of time where NS3623 was
applied. The graph shows that the compound ac-
tion was reversible. (C) Summary of average end
pulse currents fold increase at +20mV upon
NS3623 addition. Expression of either KChIP2 or
DPP6 did not result in peak current diﬀerences.
(D) Same histogram as in C, but tail currents were
measured at +40mV (numbers of replicates are
shown on the histogram).
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co-expression while leaving KChIP2.2 current density largely unaltered
(p= .915 at +40mV, Two-way ANOVA). The latter result is similar to
the ﬁnding that co-expression of DPP6 with KChIP2L had no signiﬁcant
eﬀect on current density compared to KChIP2L alone [50]. This sug-
gests that DPP6 is not only a chaperone for Kv4.3 expression levels [50]
but can also stabilize the properties of the Kv4.3/KChIP2.x complex
across diﬀerent KChIP2.x isoforms (Table 1).
It is unclear whether Ito inactivation follows a mono- or a bi-ex-
ponential time course [15,48,51] but in our experiments, mono-ex-
ponential ﬁts did not properly describe Kv4.3 inactivation. The rate of
Kv4.3 current inactivation was slowed by accessory subunit co-ex-
pression in our experiments and a larger eﬀect was observed in cells co-
expressing Kv4.3/KChIP2.1 compared to Kv4.3/KChIP2.2. Whilst
KChIP2.1 slowed inactivation (increasing both the fast and slow in-
activation time constants by ∼90% and ∼70% respectively), in cells
expressing KChIP2.2 the increase was smaller and the change in fast
component change was no longer statistically signiﬁcant. Our fast time
constant values are slightly slower than reported by Lundby et al. [32]
for experiments in a CHO expression system at 37 °C but this may be
explained by the temperature diﬀerence between our studies [52]. Our
data diﬀers from that reported in Xenopus oocytes [15], suggesting that
both the cell system and experimental temperatures may diﬀerentially
aﬀect biophysical properties.
Co-expression of either KChIP2 isoform with DPP6 did not sig-
niﬁcantly change inactivation time constants compared to Kv4.3 alone,
suggesting DPP6 opposes the kinetic increase mediated by KChIP2.x. A
similar result has been previously reported for the KChIP2.1 isoform in
oocytes [32]. However, these results diﬀer from an earlier study in CHO
cells where expression of KChIP2.2 and KChIP2.2+DPP6 showed si-
milar time constants [9]. The recovery from inactivation showed the
expected acceleration following expression of either KChIP2 isoforms or
KChIP2/DPP6 co-expression, although our time constants are faster
than reported in previous studies (albeit under somewhat diﬀerent
conditions). While our results show no signiﬁcant diﬀerence between
KChIP2.2 and KChIP2.2+DPP6 (∼7ms), Radicke et al. [52] reported
an accelerated rate of recovery when DPP6 is co-expressed with
KChIP2.2. However, their rate in CHO cells is considerably slower
(∼14ms at 37 °C) than we observed in HEK293 cells and this diﬀerence
is not explainable by the temperature diﬀerence between our studies
because the Q10 is ∼2 [52].
4.2. Eﬀect of KChIP2.2, KChIP2.1 and DPP6 on recombinant hERG
channels
In contrast to a recent report demonstrating that interactions be-
tween recombinant Kv4.3 and hERG channels can result in an increase
in IhERG density [23], co-expression of KChIP2.2, KChIP2.1 or DPP6
along with recombinant hERG channels resulted in no change in the
magnitude of IhERG. The voltage and time-dependent properties of IhERG
were generally unaltered although KChIP2.2 co-expression appeared to
accelerate hERG activation (Table 2). Furthermore, direct examination
of IhERG proﬁle under AP voltage clamp showed no signiﬁcant diﬀer-
ence in the proﬁle of current activation with and without Ito accessory
unit co-expression. Some recent studies have also investigated the ef-
fects of KChIP2 in guinea pig ventricular myocytes, which lack a
functional Ito but still expresses KChIP2 [25,53]. Knocking-down
KChIP2 expression in guinea pig ventricular myocytes leads to AP
prolongation which is not due to changes in IKr and IKs but an increase
in Cav1.2 calcium channel expression [25]. Thus although KChIP2.x
may be considered a “master regulator of cardiac repolarization” [54]
IhERG appears to escape this regulation.
4.3. Eﬀect of NS3623 on recombinant Kv4.3 and hERG channels
Hansen and colleagues characterized the eﬀect of NS3623 on IhERG
in Xenopus oocytes, reporting: (1) an increase in IhERG amplitude; (2) a
rightward shift in the voltage-dependence of inactivation and (3) a
slower onset of inactivation [35]. Finally, evaluation of a mutant
lacking inactivation (hERG-S620T) showed that the compound did not
further augment IhERG. Since no accessory subunits were co-expressed
with hERG in that study, their results support the idea of a direct in-
teraction between NS3623 and hERG protein. Further studies in guinea
pig (lacking Ito) showed NS3623 shortens the AP and decreases the
appearance of extrasystoles in perfused hearts as well as reversing drug-
induced QT prolongation, supporting the idea of some therapeutic po-
tential for this compound [45]. Our results show that Ito-modulating β-
subunits do not inﬂuence the agonism of IhERG by NS3623, consistent
with both the lack of modulatory eﬀects of KChIP2/DPP6 on the
channel and a direct α-subunit action.
In relation to the eﬀect of NS3623 on Kv4.3, our results show that
the compound augments current amplitude without accessory subunit
co-expression in contrast to ﬁndings by Hansen and colleagues using
Xenopus oocytes, who failed to detect Kv4.3 activation [35]. The reason
for this discrepancy is not clear, but may be related to the diﬀerent
expression systems and recording conditions (i.e. a mammalian cell line
at 33 °C in the present study versus Xenopus oocytes at room tempera-
ture). The concordance of our ﬁndings with the recent report by Calloe
et al. [29] using canine heart preparations (which showed an agonist
eﬀect of NS3623 on Ito) highlights the importance of using mammalian
cell expression systems for Kv4.3 studies. The rapid response to NS3623
which augments Kv4.3 current is consistent with acute eﬀects of
NS3623 on Ito leading to an increased epicardial action potential notch
seen in canine left ventricular wedge preparations [29]. Similarly, ef-
fects on current kinetics are also consistent with the primary mod-
ulatory eﬀects of NS3623 being ion channel function rather than traf-
ﬁcking/expression. Integrated charge transfer during current activation
at +40mV in the presence of NS3623 was increased by ∼50% by
KChIP 2.1/2.2 expression and this was further increased by DPP6 co-
expression to ∼100% (AUC in Table 1). Thus the addition of these
subunits signiﬁcantly augments the eﬀect of NS3623 and this raises the
possibilities of both multiple interaction sites for NS3623 and that these
eﬀects may be diﬀerent in diﬀerent regions of the heart depending of
the level/composition of subunit expression. This notion is consistent
with a prior study of the eﬀects of the related compound NS5806 on
canine Ito [47]; these were greatest in epi- and mid-myocardial cells,
which had the highest levels of KChIP2. Whether such diﬀerential ex-
pression and response could be beneﬁcial for treatment of disease
should be considered in future studies. Of course, as is the case for all
expression studies, it is not possible to rule out the possibility that the
NS3623 response may be altered by diﬀering relative expression levels
of Kv4.3 and KChIP2/DPP6 or that other accessory subunits not studied
here may contribute to the Kv4.3 response in native tissue.
4.4. Conclusions
Despite structural similarities, our data show that NS3623 binding
sites must, in some ways, be diﬀerent from the binding site(s) for
NS5806 since stimulation of Kv4.3 current by NS5806 requires the
presence of KChIP2 [47]. Our results show that, although KChIP2 iso-
forms and DPP6 proteins are not required for Kv4.3 activation by
NS3623, their presence inﬂuences the compound’s eﬀects on the rate of
current decay, dominating the overall eﬀect as reﬂected by total charge
transfer (AUC). In addition, the change in kinetics depends on β-subunit
combinations, with no change in the slow inactivation component when
only KChIP2.1 is expressed. This observation suggests KChIP2 inﬂu-
ences the gating eﬀect of NS3623 on Kv4.3. Whether this eﬀect is the
result of the drug having multiple binding sites on Kv4.3 and/or ac-
cessory subunits is unclear. Experiments with the KChIP3 isoform have
shown NS5806 can bind at a hydrophobic site within the C terminus,
modulating the interaction between KChIP3 and Kv4.3 [55]. NS5806
has an additional triﬂuoromethyl group and bromine compared to
NS3523. It is remarkable how such a small molecular diﬀerence can
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lead to such diﬀerent mechanisms of action. Further studies are
therefore needed to identify the interaction sites between Kv4.3 (and
KChIP2) and where the site(s) that mediate diﬀerential drug eﬀects on
current amplitude and kinetics are located. Elucidation of the under-
lying molecular basis of the diﬀerences between NS2623 and NS5806
could lead to new therapeutics being developed from these prototype
drugs. At this juncture, we can only suggest that NS3623 either binds to
both Kv4.3 and KChIP2 and/or that there are two binding sites on
Kv4.3 where one of them inhibits KChIP2 binding.
Funding sources
The study was funded by a programme grant from Medical Research
Council U.K. (MR/N002903/1). JCH acknowledges a University of
Bristol research fellowship.
Conﬂicts of interest
None.
Acknowledgements
The authors thank Prof. Robert Bähring for generously providing the
KChIP2.2 containing plasmid. We also thank Dr. Yi hong Zhang for cell
culture advice and Dr. Cherrie H.T. Kong for assistance with ﬁgure
preparation.
References
[1] N. Schmitt, M. Grunnet, S.-P. Olesen, Cardiac potassium channel subtypes: new
roles in repolarization and arrhythmia, Physiol. Rev. 94 (2014) 609–653.
[2] J.M. Nerbonne, Molecular physiology of cardiac repolarization, Physiol. Rev. 85
(2005) 1205–1253.
[3] C.J. Grantham, M.B. Cannell, Ca2+ inﬂux during the cardiac action potential in
guinea pig ventricular myocytes, Circ. Res. 79 (1996) 194–200.
[4] P.J. Cooper, C. Soeller, M.B. Cannell, Excitation-contraction coupling in human
heart failure examined by action potential clamp in rat cardiac myocytes, J. Mol.
Cell. Cardiol. 49 (2010) 911–917.
[5] R. Sah, R.J. Ramirez, G.Y. Oudit, D. Gidrewicz, M.G. Trivieri, C. Zobel, et al.,
Regulation of cardiac excitation-contraction coupling by action potential repolar-
ization: role of the transient outward potassium current (Ito), J. Physiol. (Lond.) 546
(2002) 5–18.
[6] N. Niwa, J.M. Nerbonne, Molecular determinants of cardiac transient outward
potassium current (Ito) expression and regulation, J. Mol. Cell. Cardiol. 48 (2010)
12–25.
[7] G.W. Abbott, X. Xu, T.K. Roepke, Impact of ancillary subunits on ventricular re-
polarization, J. Electrocardiol. 40 (2007) S42–S46.
[8] S. Radicke, D. Cotella, E. Graf, U. Banse, N. Jost, A. Varro, et al., Functional
modulation of the transient outward current Ito by KCNE β-subunits and regional
distribution in human non-failing and failing hearts, Cardiovasc. Res. 71 (2006)
695–703.
[9] S. Radicke, D. Cotella, E.M. Graf, U. Ravens, E. Wettwer, Expression and function of
dipeptidyl-aminopeptidase-like protein 6 as a putative β-subunit of human cardiac
transient outward current encoded by Kv4. 3, J. Physiol. (Lond.) 565 (2005)
751–756.
[10] W. Guo, H. Li, F. Aimond, D.C. Johns, K.J. Rhodes, J.S. Trimmer, et al., Role of
heteromultimers in the generation of myocardial transient outward K+ currents,
Circulation (2002).
[11] S.P. Patel, D.L. Campbell, Transient outward potassium current, “Ito”, phenotypes in
the mammalian left ventricle: underlying molecular, cellular and biophysical me-
chanisms, J. Physiol. (Lond.) 569 (2005) 7–39.
[12] S. Ohya, Y. Morohashi, K. Muraki, T. Tomita, M. Watanabe, T. Iwatsubo, et al.,
Molecular cloning and expression of the novel splice variants of K+ channel-in-
teracting protein 2, Biochem. Biophys. Res. Commun. 282 (2001) 96–102.
[13] N. Decher, O. Uyguner, C.R. Scherer, B. Karaman, M. Yüksel-Apak, A.E. Busch,
et al., hKChIP2 is a functional modiﬁer of hKv4.3 potassium channels: cloning and
expression of a short hKChIP2 splice variant, Cardiovasc. Res. 52 (2001) 255–264.
[14] R. Bähring, J. Dannenberg, H.C. Peters, T. Leicher, O. Pongs, D. Isbrandt, Conserved
Kv4 N-terminal domain critical for eﬀects of Kv channel-interacting protein 2.2 on
channel expression and gating, J. Biol. Chem. 276 (2001) 23888–23894.
[15] N. Decher, A.S. Barth, T. Gonzalez, K. Steinmeyer, M.C. Sanguinetti, Novel KChIP2
isoforms increase functional diversity of transient outward potassium currents, J.
Physiol. (Lond.) 557 (2004) 761–772.
[16] H.C. Kuo, C.F. Cheng, R.B. Clark, J.J. Lin, J.L. Lin, M. Hoshijima, et al., A defect in
the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of Ito
and confers susceptibility to ventricular tachycardia, Cell 107 (2001) 801–813.
[17] M.C. Sanguinetti, M. Tristani-Firouzi, hERG potassium channels and cardiac
arrhythmia, Nature 440 (2006) 463–469.
[18] M. Weerapura, S. Nattel, D. Chartier, R. Caballero, T.E. Hébert, A comparison of
currents carried by HERG, with and without coexpression of MiRP1, and the native
rapid delayed rectiﬁer current. Is MiRP1 the missing link? J. Physiol. (Lond.) 540
(2002) 15–27.
[19] T.V. McDonald, Z. Yu, Z. Ming, E. Palma, M.B. Meyers, K.W. Wang, et al., A minK-
HERG complex regulates the cardiac potassium current IKr, Nature 388 (1997)
289–292.
[20] G.W. Abbott, F. Sesti, I. Splawski, M.E. Buck, M.H. Lehmann, K.W. Timothy, et al.,
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac
arrhythmia, Cell 97 (1999) 175–187.
[21] S. Ohno, D.P. Zankov, H. Yoshida, K. Tsuji, T. Makiyama, H. Itoh, et al., N- and C-
terminal KCNE1 mutations cause distinct phenotypes of long QT syndrome, Heart
Rhyth. 4 (2007) 332–340.
[22] G.A. Gutman, K.G. Chandy, J.P. Adelman, J. Aiyar, D.A. Bayliss, D.E. Clapham,
et al., International Union of Pharmacology. XLI. Compendium of voltage-gated ion
channels: potassium channels, Pharmacol. Rev. 55 (2003) 583–586.
[23] X.-J. Zhao, C. Zhu, L.-Y. Tian, Y.-C. Fu, Y. Zhang, X. Chen, et al., Kv4.3 Modulates
the distribution of hERG, Sci Rep 7 (2017) 17757.
[24] D.M. Nassal, X. Wan, H. Liu, D. Maleski, A. Ramirez-Navarro, C.S. Moravec, et al.,
KChIP2 is a core transcriptional regulator of cardiac excitability, Elife 6 (2017)
e17304.
[25] D.M. Nassal, X. Wan, H. Liu, I. Deschênes, Myocardial KChIP2 expression in guinea
pig resolves an expanded electrophysiologic role, PLoS ONE 11 (2016) e0146561.
[26] M.B. Thomsen, C. Wang, N. Ozgen, H.-G. Wang, M.R. Rosen, G.S. Pitt, Accessory
subunit KChIP2 modulates the cardiac L-type calcium current, Circ. Res. 104 (2009)
1382–1389.
[27] M. Grunnet, Repolarization of the cardiac action potential. Does an increase in
repolarization capacity constitute a new anti-arrhythmic principle? Acta Physiol.
198 (2010) 1–48.
[28] K. Calloe, J.M. Cordeiro, J.M. Di Diego, R.S. Hansen, M. Grunnet, S.-P. Olesen,
et al., A transient outward potassium current activator recapitulates the electro-
cardiographic manifestations of Brugada syndrome, Cardiovasc. Res. 81 (2009)
686–694.
[29] K. Calloe, J.M. Di Diego, R.S. Hansen, S.A. Nagle, J.A. Treat, J.M. Cordeiro, A dual
potassium channel activator improves repolarization reserve and normalizes ven-
tricular action potentials, Biochem. Pharmacol. 108 (2016) 36–46.
[30] J.M. Cordeiro, K. Calloe, N. Moise, B. Kornreich, D. Giannandrea, J.M. Di Diego,
et al., Physiological consequences of transient outward K+ current activation
during heart failure in the canine left ventricle, J. Mol. Cell, Cardiol, 2012.
[31] H. Cheng, M.B. Cannell, J.C. Hancox, Diﬀerential responses of rabbit ventricular
and atrial transient outward current (Ito) to the Ito modulator NS5806, Physiol. Rep.
5 (2017) e13172.
[32] A. Lundby, T. Jespersen, N. Schmitt, M. Grunnet, S.P. Olesen, J.M. Cordeiro, et al.,
Eﬀect of the Ito activator NS5806 on cloned Kv4 channels depends on the accessory
protein KChIP2, Br. J. Pharmacol. 160 (2010) 2028–2044.
[33] K. Calloe, E. Nof, T. Jespersen, J.M. Di Diego, N. Chlus, S.-P. Olesen, et al.,
Comparison of the eﬀects of a transient outward potassium channel activator on
currents recorded from atrial and ventricular cardiomyocytes, J. Cardiovasc.
Electrophysiol. 22 (2011) 1057–1066.
[34] P. Bennekou, L. de Franceschi, O. Pedersen, L. Lian, T. Asakura, G. Evans, et al.,
Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte
dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle
cell disease, Blood 97 (2001) 1451–1457.
[35] R.S. Hansen, T.G. Diness, T. Christ, E. Wettwer, U. Ravens, S.-P. Olesen, et al.,
Biophysical characterization of the new human ether-a-go-go-related gene channel
opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-N“-(3-”tri-
ﬂuoromethylphenyl)urea], Mol. Pharm. 70 (2006) 1319–1329.
[36] D. Isbrandt, T. Leicher, R. Waldschütz, X. Zhu, U. Luhmann, U. Michel, et al., Gene
structures and expression proﬁles of three human KCND (Kv4) potassium channels
mediating A-type currents ITO and ISA, Genomics 64 (2000) 144–154.
[37] Z. Zhou, Q. Gong, B. Ye, Z. Fan, J.C. Makielski, G.A. Robertson, et al., Properties of
HERG channels stably expressed in HEK 293 cells studied at physiological tem-
perature, Biophys. J. 74 (1998) 230–241.
[38] Y.H. Zhang, H. Cheng, V.A. Alexeenko, C.E. Dempsey, J.C. Hancox,
Characterization of recombinant hERG K+ channel inhibition by the active meta-
bolite of amiodarone desethyl-amiodarone, J. Electrocardiol. 43 (2010) 440–448.
[39] C.Y. Du, A. Harchi El, Y.H. Zhang, C.H. Orchard, J.C. Hancox, Pharmacological
inhibition of the hERG potassium channel is modulated by extracellular but not
intracellular acidosis, J. Cardiovasc. Electrophysiol. 22 (2011) 1163–1170.
[40] M.J. McPate, H. Zhang, I. Adeniran, J.M. Cordeiro, H.J. Witchel, J.C. Hancox,
Comparative eﬀects of the short QT N588K mutation at 37 degrees C on hERG K+
channel current during ventricular, Purkinje ﬁbre and atrial action potentials: an
action potential clamp study, J. Physiol. Pharmacol. 60 (2009) 23–41.
[41] P.S. Spector, Fast inactivation causes rectiﬁcation of the IKr channel, J. Gen. Physiol.
107 (1996) 611–619.
[42] S. Liu, R.L. Rasmusson, D.L. Campbell, S. Wang, H.C. Strauss, Activation and in-
activation kinetics of an E-4031-sensitive current from single ferret atrial myocytes,
Biophys. J. 70 (1996) 2704–2715.
[43] A.G. Teschemacher, E.P. Seward, J.C. Hancox, H.J. Witchel, Inhibition of the cur-
rent of heterologously expressed HERG potassium channels by imipramine and
amitriptyline, Br. J. Pharmacol. 128 (1999) 479–485.
[44] C. Du, A. Harchi El, H. Zhang, J.C. Hancox, Modiﬁcation by KCNE1 variants of the
hERG potassium channel response to premature stimulation and to pharmacological
inhibition, Physiol. Rep. 1 (2013) e00175.
[45] R.S. Hansen, S.-P. Olesen, L.C.B. Rønn, M. Grunnet, In vivo eﬀects of the IKr agonist
S. Lainez et al. Biochemical Pharmacology 150 (2018) 120–130
129
NS3623 on cardiac electrophysiology of the Guinea Pig, J. Cardiovasc. Pharmacol.
52 (2008) 35–41.
[46] I. Deschenes, Regulation of Kv4.3 current by KChIP2 splice variants: a component of
native cardiac Ito? Circulation 106 (2002) 423–429.
[47] K. Calloe, E. Soltysinska, T. Jespersen, A. Lundby, C. Antzelevitch, S.-P. Olesen,
et al., Diﬀerential eﬀects of the transient outward K+ current activator NS5806 in
the canine left ventricle, J. Mol. Cell. Cardiol. 48 (2010) 191–200.
[48] S.P. Patel, R. Parai, R. Parai, D.L. Campbell, Regulation of Kv4.3 voltage-dependent
gating kinetics by KChIP2 isoforms, J. Physiol. (Lond.) 557 (2004) 19–41.
[49] G.W. Abbott, β Subunits functionally diﬀerentiate human Kv4.3 potassium channel
splice variants, Front. Physiol. 8 (2017) 66.
[50] S. Radicke, M. Vaquero, R. Caballero, R. Gómez, L. Núñez, J. Tamargo, et al., Eﬀects
of MiRP1 and DPP6 beta-subunits on the blockade induced by ﬂecainide of Kv4.3/
KChIP2 channels, Br. J. Pharmacol. 154 (2008) 774–786.
[51] S.P. Patel, D.L. Campbell, H.C. Strauss, Elucidating KChIP eﬀects on Kv4.3 in-
activation and recovery kinetics with a minimal KChIP2 isoform, J. Physiol. (Lond.)
545 (2002) 5–11.
[52] S. Radicke, T. Riedel, D. Cotella, K. Turnow, U. Ravens, M. Schaefer, et al.,
Accessory subunits alter the temperature sensitivity of Kv4.3 channel complexes, J.
Mol. Cell. Cardiol. 56 (2013) 8–18.
[53] I. Findlay, Is there an A-type K+ current in guinea pig ventricular myocytes? Am. J.
Physiol. Heart Circ. Physiol. 284 (2003) H598–H604.
[54] D.M. Nassal, X. Wan, H. Liu, K.R. Laurita, I. Deschênes, KChIP2 regulates the car-
diac Ca2+ transient and myocyte contractility by targeting ryanodine receptor ac-
tivity, PLoS ONE 12 (2017) e0175221.
[55] W.G. Gonzalez, K. Pham, J. Miksovska, Modulation of the voltage-gated potassium
channel (Kv4.3) and the auxiliary protein (KChIP3) interactions by the current
activator NS5806, J. Biol. Chem. 289 (2014) 32201–32213.
S. Lainez et al. Biochemical Pharmacology 150 (2018) 120–130
130
